Jazz Enters Oncology Market With EUSA Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Jazz strays away from its CNS focus with a $700 million acquisition of EUSA Pharma, adding the specialty pharma’s oncology product to its portfolio.